DCF Advisers’s Viridian Therapeutics VRDN Stock Holding History

DCF Advisers’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$698K	Buy	38,000 +5,850	+18%	+$94.3K	0.12%	75
2026 Q1	$629K	Sell	32,150 -20,550	-39%	-$610K	0.17%	70
2025 Q4	$1.64M	Sell	52,700 -9,329	-15%	-$256K	0.44%	55
2025 Q3	$1.34M	Hold	62,029	–	–	0.43%	57
2025 Q2	$867K	Hold	62,029	–	–	0.4%	57
2025 Q1	$836K	Buy	62,029 +32,279	+109%	+$550K	0.4%	60
2024 Q4	$570K	Buy	29,750 +15,250	+105%	+$332K	0.28%	67
2024 Q3	$330K	Sell	14,500 -3,250	-18%	-$53.1K	0.13%	80
2024 Q2	$231K	Buy	17,750 +3,250	+22%	+$45K	0.12%	84
2024 Q1	$254K	Buy	14,500 +5,000	+53%	+$96.9K	0.13%	72
2023 Q4	$207K	Sell	9,500 -4,000	-30%	-$63.1K	0.11%	72
2023 Q3	$207K	Sell	13,500 -5,500	-29%	-$105K	0.11%	83
2023 Q2	$452K	Buy	+19,000	New	+$487K	0.24%	64

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

DCF Advisers's VRDN Position: Q2 2026 in Review

DCF Advisers increased its Viridian Therapeutics (VRDN) stake by 18% in Q2 2026, buying an estimated $94.3K and bringing the position to 38,000 shares worth $698K. The position accounts for 0.12% of the portfolio, ranked #75.

DCF Advisers first reported a position in VRDN in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.64M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

DCF Advisers held 38,000 shares of Viridian Therapeutics worth $698K as of Q2 2026.
DCF Advisers bought 5,850 Viridian Therapeutics shares in Q2 2026, an estimated $94.3K.
Viridian Therapeutics made up 0.12% of DCF Advisers's portfolio in Q2 2026, its #75 holding.
DCF Advisers first reported a position in Viridian Therapeutics in Q2 2023 and has held it in 13 quarters since.
DCF Advisers's Viridian Therapeutics position peaked at $1.64M in Q4 2025.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.